Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 1;5(1):vdad014.
doi: 10.1093/noajnl/vdad014. eCollection 2023 Jan-Dec.

Metastatic high-grade meningioma: A case report and review of risk factors for metastasis

Destiny D Bailey  1 , Eric Y Montgomery  1 , Tomas Garzon-Muvdi  2
Affiliations

Metastatic high-grade meningioma: A case report and review of risk factors for metastasis

Destiny D Bailey et al. Neurooncol Adv. .
No abstract available

Keywords: extracranial metastasis; meningioma; metastatic; recurrent meningioma.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1.
Figure 1.
(A) MR AX T1 Flair on 3/13/2020 showing multilobulated mass along left parietal/occipital lobes and extracranial mass. (B) MR SAG T1 Flair on 3/13/2020 showing multilobulated mass along left parietal/occipital lobes and extracranial mass. (C) MR COR T1 Flair on 3/13/2020 showing multilobulated mass along left parietal/occipital lobes. (D) MR AX T1 Flair post-contrast on 03/13/2020 shows new frontal lesion. (E) MR SAG T1 Flair post-contrast on 03/13/2020 shows new frontal lesion.
Figure 2.
Figure 2.
(A) MR SAG T1 Flair post-contrast on 10/10/2020 shows the parafalcine lesion. (B) MR COR T1 Flair post-contrast on 10/10/2020 shows growth of parafalcine lesion and invasion into superior sagittal sinus. (C) MR AX T1 Flair post-contrast on 10/10/2020 shows the parafalcine and frontal lesion. (D) MR SAG T1 Flair post-contrast on 10/10/2020 shows the increase in size of the frontal lesion. (E) MR COR T1 Flair post-contrast on 10/10/2020 shows the increase in size of the frontal lesion.
Figure 3.
Figure 3.
(A) MR on 09/08/2021 shows liver metastasis. (B) MR on 09/08/2021 shows kidney metastasis. (C) MR on 09/08/2021 shows spinal metastasis. (D) DOTATE PET on 09/10/2021 shows liver metastases. (E) DOTATE PET on 09/10/2021 shows sacral and vertebral metastases.
See this image and copyright information in PMC

References

    1. Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 2020;22(12 Suppl 2):iv1–iv96. - PMC - PubMed
    1. Ostrom QT, Truitt G, Gittleman H, et al. Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014. Neurooncol Pract. 2020;7(3):306–312. - PMC - PubMed
    1. Dalle Ore CL, Magill ST, Yen AJ, et al. Meningioma metastases: incidence and proposed screening paradigm. J Neurosurg. 2019;132(5):1447–1455. - PubMed
    1. Garzon-Muvdi T, Yang W, Lim M, Brem H, Huang J.. Atypical and anaplastic meningioma: outcomes in a population based study. J Neurooncol. 2017;133(2):321–330. - PubMed
    1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. - PMC - PubMed

LinkOut - more resources